| Not Yet Recruiting | A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Recept NCT07294339 | Peking University People's Hospital | N/A |
| Not Yet Recruiting | ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673 | Laura Huppert, MD, BA | Phase 2 |
| Not Yet Recruiting | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment NCT07366112 | Peking University People's Hospital | Phase 2 |
| Recruiting | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215 | Kristina A. Fanucci | Phase 2 |
| Recruiting | Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea NCT07264998 | Hubei Cancer Hospital | — |
| Recruiting | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cance NCT06970912 | Peking University People's Hospital | Phase 2 |
| Recruiting | A Study of Revaree Plus in People With Breast Cancer NCT07042581 | Memorial Sloan Kettering Cancer Center | Phase 4 |
| Active Not Recruiting | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer NCT06878248 | Calibr, a division of Scripps Research | Phase 1 |
| Recruiting | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growt NCT06756932 | BeOne Medicines | Phase 1 |
| Not Yet Recruiting | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer NCT06470672 | Fudan University | Phase 2 |
| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer NCT06518837 | Rutgers, The State University of New Jersey | Phase 2 |
| Recruiting | Study of XB010 in Subjects With Solid Tumors NCT06545331 | Exelixis | Phase 1 |
| Not Yet Recruiting | Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. NCT06338644 | Helwan University | — |
| Recruiting | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543 | Reshma L. Mahtani, D.O. | Phase 2 |
| Recruiting | DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients NCT06388122 | Mayo Clinic | — |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195 | BeiGene | Phase 1 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Active Not Recruiting | Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer NCT06144944 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Recruiting | ETHAN - ET for Male BC NCT05501704 | Jose Pablo Leone | Phase 2 |
| Completed | Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer NCT06040593 | Daiichi Sankyo | — |
| Unknown | Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian F NCT05801705 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860 | Baylor Breast Care Center | Phase 2 |
| Suspended | Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer NCT05503108 | Leiden University Medical Center | Phase 3 |
| Recruiting | VS-6766+Abema+Fulv in Met HR+/HER- BC NCT05608252 | Adrienne G. Waks | Phase 1 / Phase 2 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic A NCT05573126 | Ellipses Pharma | Phase 1 / Phase 2 |
| Recruiting | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA I NCT07073755 | Hunan Cancer Hospital | — |
| Unknown | Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient NCT05651087 | Gun Oh Chong | N/A |
| Recruiting | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Ad NCT05452213 | Institut fuer Frauengesundheit | Phase 4 |
| Recruiting | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/H NCT05766410 | National Taiwan University Hospital | Phase 2 |
| Recruiting | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor NCT05467891 | Oana Danciu | Phase 2 |
| Recruiting | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584 | University of California, Irvine | Phase 2 |
| Terminated | A Study in Patients With Advanced Breast Cancer NCT04942054 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Completed | RWE About QOL and Compliance of Patients With OFS in China NCT05122377 | Fudan University | — |
| Unknown | Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors NCT05860621 | Grupo Lusófona | N/A |
| Recruiting | Study of Screening Brain MRIs in Stage IV Breast Cancer NCT05115474 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Active Not Recruiting | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer NCT06570031 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients NCT04997941 | Seoul National University Hospital | Phase 2 |
| Completed | Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer NCT05064085 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Withdrawn | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Active Not Recruiting | Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive E NCT05165225 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) NCT04925284 | Exelixis | Phase 1 |
| Unknown | Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer NCT04891731 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Active Not Recruiting | Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer NCT04872985 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Active Not Recruiting | TH1902 in Patients With Advanced Solid Tumors NCT04706962 | Theratechnologies | Phase 1 |
| Active Not Recruiting | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anato NCT04569747 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - R NCT06463626 | Novartis | — |
| Completed | WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 I NCT03854903 | Georgetown University | Phase 1 |
| Active Not Recruiting | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) NCT03401385 | Daiichi Sankyo Co., Ltd. | Phase 1 |
| Completed | CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO NCT03227328 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Completed | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer NCT02675231 | Eli Lilly and Company | Phase 2 |
| Completed | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or NCT01698918 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. NCT01602380 | AstraZeneca | Phase 3 |
| Completed | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, NCT01177397 | Celgene | Phase 1 / Phase 2 |
| Withdrawn | Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormo NCT00615524 | GlaxoSmithKline | Phase 2 |